Company profile
Lexeo Therapeutics, Inc. Common Stock
NASDAQ: LXEO · Healthcare · Biotechnology
PublicHQ New York City, CIK 0001907108Reports USD
#908 of 1,418 Healthcare companies by revenue
EA Score
37DFH 44DQ 24GM —SS 45
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$100.0M
Employees
59
as of 2026-08-12
Market cap
$375.3M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$654.0k$654.0k2023
Net income-$100.0M-$100.0M2025
Operating income-$109.3M-$109.3M2025
Total assets$268.7M$268.7M2025
Liabilities$22.0M$22.0M2025
Equity$246.7M$246.7M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lexeo Therapeutics, Inc. Common Stock’s revenue?
Lexeo Therapeutics, Inc. Common Stock booked $654.0k in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -15284.6% net margin.
Peers · Healthcare
Adia Nutrition, Inc.29DUnicycive Therapeutics, Inc.32DSETO Holdings, Inc.54DPolomar Health Services, Inc.28DMarizyme, Inc.——BioXcel Therapeutics, Inc.27DKey facts
CEOR. Nolan Townsend
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, null
ExchangeNASDAQ: LXEO
Employees59
IPO date2023-11-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.